{{Rsnum
|rsid=2395402
|Gene=LEMD2
|Chromosome=6
|position=33785896
|Orientation=minus
|GMAF=0.4793
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=LEMD2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 27.4 | 46.9 | 25.7
| HCB | 2.9 | 29.9 | 67.2
| JPT | 2.7 | 31.0 | 66.4
| YRI | 54.4 | 41.5 | 4.1
| ASW | 45.6 | 47.4 | 7.0
| CHB | 2.9 | 29.9 | 67.2
| CHD | 1.8 | 21.1 | 77.1
| GIH | 9.9 | 55.4 | 34.7
| LWK | 69.1 | 30.0 | 0.9
| MEX | 25.9 | 55.2 | 19.0
| MKK | 23.7 | 46.8 | 29.5
| TSI | 27.5 | 43.1 | 29.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2395402
|Name_s=
|Gene_s=LEMD2
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=Risk or phenotype-associated allele: G allele. Phenotype: Carbamazepine (CBZ)-induced hypersensitivity syndrome (HSS). Study size: 157. Study population/ethnicity: 13 CBZ-induced HSS cases and 144 CBZ-tolerant controls of Chinese descent. Significance metric(s): p = 0.002381, OR = 3.86. Type of association: GN; PD; TOX; ADR.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Drug Hypersensitivity
|Curation Level=Curated
|PharmGKB Accession ID=PA165291964
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2395402
|overall_frequency_n=63
|overall_frequency_d=128
|overall_frequency=0.492188
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}